Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | PNP | P00491 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 9/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098413 | 0.91 | HINT1 (0.67) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL6239924 | 0.91 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2533738 | 0.90 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL6889003 | 0.90 | HINT1 (0.70) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2335177 | 0.89 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL1138984 | 0.89 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL6245258 | 0.89 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL5501200 | 0.89 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3925834 | 0.89 | HINT1 (0.64) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL1424945 | 0.88 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3454895-B1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NAJIT TECH INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11844832-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | NAJIT TECHNOLOGIES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20210196812-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | Najít Technologies, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-10744198-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | NAJIT TECHNOLOGIES, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| CN-110199023-A | Ahlport syndrome medicine | 第一三共株式会社 | 2019-09-03 | — | — | CN | disclosed |
| US-20190201520-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-04 | — | — | US | disclosed |
| EP-3454895-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | Najit Technologies, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017197034-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NAJIT TECHNOLOGIES, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | disclosed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-0977832-A4 | METHOD FOR INACTIVATING A VIRUS | VI TECHNOLOGIES INC (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6252048-B1 | FUSION PROTEIN FOR THE TREATMENT AND PREVENTION OF CANCER | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE | 2001-06-26 | — | — | US | disclosed |
| EP-0977832-A1 | METHOD FOR INACTIVATING A VIRUS | Pentose Pharmaceuticals, Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5891705-A | Method for inactivating a virus | PENTOSE PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998045415-A1 | METHOD FOR INACTIVATING A VIRUS | PENTOSE PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998017684-A2 | DNA SEQUENCES ENCODING FUSIONS OF DNA REPAIR PROTEINS AND USES THEREOF | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1998-04-30 | — | — | WO | disclosed |
| US-5622945-A | Rubyrin macrocycles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1996021665-A1 | TURCASARINS, NOVEL EXPANDED PORPHYRINS, AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-07-18 | — | — | WO | disclosed |
| US-5410045-A | As anion chelators, receptors and transporters | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210196812-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | OGG1, EIF2AK2, AS3MT | HINT1 2419/4885NT5E 2675/4885GSK3A 3510/4885 |
| US-20190201520-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | OGG1, EIF2AK2, AS3MT | HINT1 2457/4885NT5E 2696/4885GSK3A 3574/4885 |
| US-11844832-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | OGG1, EIF2AK2, AS3MT | HINT1 2419/4885NT5E 2675/4885GSK3A 3510/4885 |
| US-10744198-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | OGG1, EIF2AK2, AS3MT | HINT1 2457/4885NT5E 2696/4885GSK3A 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.